- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05329194
Effectiveness and Safety Study of Tezepelumab in Adults & Adolescent Participants With Severe Asthma in the United States (PASSAGE)
A Multicenter, Single-arm, Open-label, Post-Authorization, Phase 4 Effectiveness and Safety Study of Tezepelumab in Adult and Adolescent Participants With Severe Asthma Including Several Under-Studied Populations in the United States (PASSAGE)
Study Overview
Detailed Description
Study Type
Enrollment (Estimated)
Phase
- Phase 4
Contacts and Locations
Study Contact
- Name: AstraZeneca Clinical Study Information Center
- Phone Number: 1-877-240-9479
- Email: information.center@astrazeneca.com
Study Locations
-
-
Alabama
-
Hoover, Alabama, United States, 35244
- Withdrawn
- Research Site
-
Mobile, Alabama, United States, 36608
- Withdrawn
- Research Site
-
-
Arizona
-
Gilbert, Arizona, United States, 85234
- Withdrawn
- Research Site
-
-
California
-
La Jolla, California, United States, 92093
- Not yet recruiting
- Research Site
-
Long Beach, California, United States, 90815
- Recruiting
- Research Site
-
Rancho Mirage, California, United States, 92270
- Recruiting
- Research Site
-
Westminster, California, United States, 92683
- Recruiting
- Research Site
-
Whittier, California, United States, 90603
- Recruiting
- Research Site
-
-
Colorado
-
Colorado Springs, Colorado, United States, 80907
- Recruiting
- Research Site
-
-
Connecticut
-
New Haven, Connecticut, United States, 06510
- Recruiting
- Research Site
-
-
District of Columbia
-
Washington, District of Columbia, United States, 20037
- Recruiting
- Research Site
-
-
Illinois
-
Chicago, Illinois, United States, 60611
- Recruiting
- Research Site
-
-
Kentucky
-
Lexington, Kentucky, United States, 40509
- Recruiting
- Research Site
-
-
Louisiana
-
New Orleans, Louisiana, United States, 70112
- Recruiting
- Research Site
-
-
Maryland
-
Upper Marlboro, Maryland, United States, 20772
- Recruiting
- Research Site
-
White Marsh, Maryland, United States, 21162
- Withdrawn
- Research Site
-
-
Michigan
-
Ann Arbor, Michigan, United States, 48109
- Recruiting
- Research Site
-
Ypsilanti, Michigan, United States, 48197
- Recruiting
- Research Site
-
-
Minnesota
-
Saint Paul, Minnesota, United States, 55109
- Recruiting
- Research Site
-
-
Missouri
-
Saint Louis, Missouri, United States, 63110
- Recruiting
- Research Site
-
-
Nebraska
-
Lincoln, Nebraska, United States, 68505
- Recruiting
- Research Site
-
Omaha, Nebraska, United States, 68114
- Recruiting
- Research Site
-
-
New York
-
Bronx, New York, United States, 10465
- Withdrawn
- Research Site
-
Hollis, New York, United States, 11423
- Recruiting
- Research Site
-
Horseheads, New York, United States, 14845
- Withdrawn
- Research Site
-
Rochester, New York, United States, 14642
- Recruiting
- Research Site
-
Valhalla, New York, United States, 10595
- Recruiting
- Research Site
-
-
North Carolina
-
Chapel Hill, North Carolina, United States, 27514
- Recruiting
- Research Site
-
Durham, North Carolina, United States, 27709
- Withdrawn
- Research Site
-
Wilmington, North Carolina, United States, 28401
- Recruiting
- Research Site
-
-
Ohio
-
Cincinnati, Ohio, United States, 45229
- Withdrawn
- Research Site
-
Toledo, Ohio, United States, 43617
- Recruiting
- Research Site
-
-
Oklahoma
-
Oklahoma City, Oklahoma, United States, 73120
- Recruiting
- Research Site
-
-
Pennsylvania
-
Altoona, Pennsylvania, United States, 16602
- Recruiting
- Research Site
-
Philadelphia, Pennsylvania, United States, 19140
- Recruiting
- Research Site
-
-
Rhode Island
-
Warwick, Rhode Island, United States, 02886
- Withdrawn
- Research Site
-
-
South Carolina
-
Greenville, South Carolina, United States, 29607
- Recruiting
- Research Site
-
-
Tennessee
-
Hendersonville, Tennessee, United States, 37075
- Recruiting
- Research Site
-
-
Texas
-
Dallas, Texas, United States, 75246
- Withdrawn
- Research Site
-
Fort Worth, Texas, United States, 76107
- Recruiting
- Research Site
-
McKinney, Texas, United States, 75069
- Recruiting
- Research Site
-
San Antonio, Texas, United States, 78229
- Recruiting
- Research Site
-
-
Virginia
-
Charlottesville, Virginia, United States, 22903
- Recruiting
- Research Site
-
-
Washington
-
Vancouver, Washington, United States, 98664
- Recruiting
- Research Site
-
-
Wisconsin
-
Madison, Wisconsin, United States, 53792
- Withdrawn
- Research Site
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Male or female participant must be 12 years of age or older, at the time of signing the informed consent form or assent.
- Documented physician-diagnosed asthma for at least 12 months prior to enrollment and confirmed by the Investigator not to be due to alternative diagnoses.
- Documented treatment with medium- to high dose ICS as per Global Initiative for Asthma (GINA) guidelines (GINA 2021) for at least 12 months prior to enrollment.
- Use of additional asthma maintenance controller medication(s) in addition to ICS for at least 12 months prior to enrollment. The additional maintenance controller medication may be contained in a combination product (eg, ICS/ long-acting β-agonist (LABA)).
- Documented history of at least 2 asthma exacerbations during the 12 months prior to enrollment.
- Physician decision that participant is eligible for treatment with tezepelumab according to the approved United States product insert (USPI).
- Currently receiving care from specialist physicians (eg, pulmonologists and/or allergists).
- Provision of signed and dated written informed consent form.
Exclusion Criteria:
- Any contraindication to tezepelumab as per the US approved product label or in the opinion of the Investigator.
- Comorbid diagnosis of severe or very severe chronic obstructive pulmonary disease (COPD) per GOLD guidelines (GOLD 2021).
- Use of biologics that are approved for the treatment of asthma within 4 months or 5 half- lives (whichever is longer) prior to enrollment.
- Participation in an interventional clinical trial for asthma within 12 months prior to enrollment.
- Judgment by the Investigator that the participant is unlikely to comply with study procedures, restrictions, and requirements.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Tezepelumab
Participants will be receiving 210 mg of tezepelumab every 4 weeks (Q4W) from Week 0 until Week 48.
|
Participants will be receiving subcutaneous injection of tezepelumab.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Annualized asthma exacerbation rate (AAER)
Time Frame: Baseline period up to study Week 52
|
Asthma exacerbation will be defined by worsening of asthma symptoms that leads to temporary bolus/burst of systemic corticosteroids for at least 3 consecutive days, or an emergency department (ED) or urgent care visit due to asthma that required systemic corticosteroid (SCS), and/or inpatient hospitalization (≥24 hours) due to asthma. The AAER is based on exacerbations reported by the investigator over 52 weeks. The exacerbation rate will be compared between the 12 month period before (baseline period) and the 12 month period after initiation of tezepelumab (up to study Week 52 - study period). |
Baseline period up to study Week 52
|
Proportion of participants with asthma exacerbations
Time Frame: Baseline period up to study Week 52
|
The proportion of participants with asthma exacerbations in the 12 month periods before (baseline period) and after initiation of tezepelumab (study period) (up to study Week 52 - study period) will be assessed.
|
Baseline period up to study Week 52
|
Proportion of participants who completed the 52 -week study period with any reduction in total number of asthma exacerbations
Time Frame: Baseline period up to study Week 52
|
The proportion of participants who completed the 52 -week study period following tezepelumab initiation with any reduction, at least 50% reduction, and 100% reduction in total number of asthma exacerbations will be assessed.
|
Baseline period up to study Week 52
|
Cumulative asthma exacerbation days
Time Frame: Baseline period up to study Week 52
|
The cumulative asthma exacerbation days over 52 weeks before (baseline period) and after initiation of tezepelumab (study period) will be assessed.
|
Baseline period up to study Week 52
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Pre-bronchodilator (pre-BD) forced expiratory volume in 1 second (FEV1)
Time Frame: Baseline (Week 0), Week 24, Week 52
|
Lung function (FEV1) will be measured pre-bronchodilator (pre-BD) by spirometry test.
|
Baseline (Week 0), Week 24, Week 52
|
Change from baseline in pre-bronchodilator FEV1
Time Frame: Baseline (Week 0), Week 24, Week 52
|
Change from baseline in pre-bronchodilator FEV1 will be assessed as lung function parameters after initiation of tezepelumab.
|
Baseline (Week 0), Week 24, Week 52
|
Asthma Control Questionnaire (ACQ-6)
Time Frame: Baseline (Week 0), Week 24, Week 52
|
The ACQ-6 is a shortened version of the ACQ that assesses the adequacy of asthma control and change in asthma control which occurs spontaneously or as a result of treatment. ACQ assesses symptoms and rescue bronchodilator use. Questions are weighted equally and scored from 0 (totally controlled) to 6 (severely uncontrolled). The mean ACQ-6 score is the mean of the responses. |
Baseline (Week 0), Week 24, Week 52
|
Asthma Impairment and Risk Questionnaire (AIRQ)
Time Frame: Baseline (Week 0), Week 24, Week 52
|
The Asthma Impairment and Risk Questionnaire (AIRQ) is a PRO tool intended to identify participants 12 years and older whose health may be at risk because of uncontrolled asthma. It has 10 questions that ask about respiratory symptoms, activity limitation, sleep, rescue medication use, social activities, exercise, difficulty controlling asthma, and exacerbations. All items have a yes/no response option and the tool is scored by summing the total number of 'yes' responses. This sum score is used to assess level of asthma control where: 0-1 is well controlled, 2-4 is not well controlled, and 5-10 is very poorly controlled. Thus, a higher score indicates worse control status. |
Baseline (Week 0), Week 24, Week 52
|
St. George's Respiratory Questionnaire (SGRQ)
Time Frame: Baseline (Week 0), Week 24, Week 52
|
The SGRQ is a 50-item PRO instrument developed to measure the health status of participants with airway obstruction diseases. The questionnaire is divided into 2 parts: part 1 consists of 8 items pertaining to the severity of respiratory symptoms in the preceding 4 weeks; part 2 consists of 42 items related to the daily activity and psychosocial impacts of the individual's respiratory condition. The SGRQ yields a total score and 3 components scores (symptoms, activity, and impacts). The total score indicates the impact of disease on overall health status. This total score is expressed as a percentage of overall impairment, in which 100 represents the worst possible health status and 0 indicates the best possible health status. Likewise, the domain scores range from 0 to 100, with higher scores indicative of greater impairment. |
Baseline (Week 0), Week 24, Week 52
|
Change from baseline in ACQ-6 score
Time Frame: Baseline (Week 0), Week 24, Week 52
|
Change from baseline in ACQ-6 score will be assessed.
|
Baseline (Week 0), Week 24, Week 52
|
Change from baseline in AIRQ score
Time Frame: Baseline (Week 0), Week 24, Week 52
|
Change from baseline in AIRQ score will be assessed.
|
Baseline (Week 0), Week 24, Week 52
|
Change from baseline in SGRQ score
Time Frame: Baseline (Week 0), Week 24, Week 52
|
Change from baseline in SGRQ score will be assessed.
|
Baseline (Week 0), Week 24, Week 52
|
Proportion of AIRQ responders
Time Frame: Baseline (Week 0), Week 24, Week 52
|
AIRQ responders is defined as participants who achieve ≥1 minimum clinically important difference (MCID).
|
Baseline (Week 0), Week 24, Week 52
|
Proportion of SGRQ responders
Time Frame: Baseline (Week 0), Week 24, Week 52
|
SGRQ responders is defined as participants who achieve ≥1 minimum clinically important difference (MCID).
|
Baseline (Week 0), Week 24, Week 52
|
Time to first asthma exacerbation
Time Frame: Week 0 to Week 52
|
The time to first exacerbation after initiation of tezepelumab will be assessed.
|
Week 0 to Week 52
|
Rate of asthma exacerbations associated with hospitalizations
Time Frame: Baseline period up to study Week 52
|
The rate of asthma exacerbations associated with hospitalization over 52 weeks before (baseline period) and after initiation of tezepelumab (study period) will be assessed.
|
Baseline period up to study Week 52
|
Rate of asthma exacerbations associated with emergency department /urgent care (ED/UC) visits
Time Frame: Baseline period up to study Week 52
|
The rate of asthma exacerbations associated with ED/UC visits over 52 weeks before (baseline period) and after initiation of tezepelumab (study period) will be assessed.
|
Baseline period up to study Week 52
|
Rate of asthma exacerbations associated with hospitalizations or ED/UC visits over
Time Frame: Baseline period up to study Week 52
|
The rate of asthma exacerbations associated with hospitalizations or ED/UC visits over 52 weeks before (baseline period) and after initiation of tezepelumab (study period) will be assessed.
|
Baseline period up to study Week 52
|
Proportion of participants with asthma exacerbations associated with hospitalizations or ED/UC visits
Time Frame: Baseline period up to study Week 52
|
The proportion of participants with asthma exacerbations associated with hospitalizations or ED/UC visits in in the 12-month periods before (baseline period) and after initiation of tezepelumab (study period) (up to study Week 52) will be assessed.
|
Baseline period up to study Week 52
|
Cumulative asthma exacerbation days associated with hospitalizations or ED/UC visits
Time Frame: Baseline period up to study Week 52
|
The cumulative asthma exacerbation days associated with hospitalizations or ED/UC over 52 weeks before (baseline period) and after initiation of tezepelumab (study period) will be assessed.
|
Baseline period up to study Week 52
|
Proportion of pre-BD FEV1 responders
Time Frame: Baseline (Week 0), Week 24, Week 52
|
Proportion of pre-BD FEV1 responders is defined as participants who achieve either at least 5% or 100 mL improvement from baseline.
|
Baseline (Week 0), Week 24, Week 52
|
Proportion of ACQ-6 responders
Time Frame: Baseline (Week 0), Week 24, Week 52
|
ACQ-6 responders are defined as participants who achieve >=1 clinically important difference (MCID).
|
Baseline (Week 0), Week 24, Week 52
|
Proportion of participants who require any systemic corticosteroid (SCS) use
Time Frame: Baseline period up to study Week 52
|
Proportion of participants who require any SCS use in the 12-month periods before (baseline period) and after initiation of tezepelumab (up to study Week 52 -study period) will be assessed.
|
Baseline period up to study Week 52
|
Cumulative annualized SCS dose
Time Frame: Baseline period up to study Week 52
|
Cumulative annualized SCS dose in the 12-month periods before (baseline period) and after initiation of tezepelumab (up to study Week 52- study period) will be assessed.
|
Baseline period up to study Week 52
|
Proportion of participants who require longer-term (>30 consecutive days) SCS use
Time Frame: Baseline period up to study Week 52
|
Proportion of participants who require longer-term (>30 consecutive days) SCS use in the 12-month periods before (baseline period) and after initiation of tezepelumab (up to study Week 52- study period) will be assessed.
|
Baseline period up to study Week 52
|
Number and type of asthma-related healthcare resource utilization (HRU)
Time Frame: Baseline period up to study Week 52
|
Number and type of asthma-related HRU in the 12-month period before (baseline period) and after initiation of tezepelumab (up to study Week 52- study period) will be assessed.
|
Baseline period up to study Week 52
|
Duration of asthma-related hospitalizations
Time Frame: Baseline period up to study Week 52
|
Duration of asthma-related hospitalization in the 12-month period before (baseline period) and after initiation of tezepelumab (up to study Week 52-study period) will be assessed.
|
Baseline period up to study Week 52
|
AAER for asthma exacerbations (subgroups of participants)
Time Frame: Baseline period up to study Week 52
|
The AAER based on asthma exacerbations in the 12-month period before (baseline period) and after initiation of tezepelumab (up to study Week 52- study period) will be assessed in the following subgroups of participants: Blood eosinophil count (BEC) ≥300 cells/microliter; BEC <300 cells/microliter; With a clinically-relevant allergy to a perennial aeroallergen; Without a clinically-relevant allergy to a perennial aeroallergen; Participants who identify as Black/African American; Adolescents (12-17 years); Comorbid diagnosis of mild to moderate COPD; Significant smoking history (≥10 pack-years of smoking).
|
Baseline period up to study Week 52
|
Proportion of participants with asthma exacerbations (subgroups of participants)
Time Frame: Baseline period up to study Week 52
|
The proportion of participants with asthma exacerbations in the 12-month period before (baseline period) and after initiation of tezepelumab (up to study Week 52- study period) will be assessed in the following subgroups of participants: BEC ≥300 cells/microliter; BEC <300 cells/microliter; With a clinically-relevant allergy to a perennial aeroallergen; Without a clinically-relevant allergy to a perennial aeroallergen; Participants who identify as Black/African American; Adolescents (12-17 years); Comorbid diagnosis of mild to moderate COPD; Significant smoking history (≥10 pack-years of smoking).
|
Baseline period up to study Week 52
|
Proportion of participants who completed the 52 -week study with any reduction in total number of asthma exacerbations (subgroups of participants)
Time Frame: Week 0 to Week 52
|
The proportion of participants who completed the 52 -week study period following tezepelumab initiation with any reduction, at least 50% reduction, and 100% reduction in total number of asthma exacerbations will be assessed in the following subgroups of participants: BEC ≥300 cells/microliter; BEC <300 cells/microliter; With a clinically-relevant allergy to a perennial aeroallergen; Without a clinically-relevant allergy to a perennial aeroallergen; Participants who identify as Black/African American; Adolescents (12-17 years); Comorbid diagnosis of mild to moderate COPD; Significant smoking history (≥10 pack-years of smoking).
|
Week 0 to Week 52
|
Cumulative asthma exacerbation days (subgroups of participants)
Time Frame: Baseline period up to study Week 52
|
The cumulative asthma exacerbation days over 52 weeks before (baseline period) and after initiation of tezepelumab (study period) will be assessed in the following subgroups of participants: BEC ≥300 cells/microliter; BEC <300 cells/microliter; With a clinically-relevant allergy to a perennial aeroallergen; Without a clinically-relevant allergy to a perennial aeroallergen; Participants who identify as Black/African American; Adolescents (12-17 years); Comorbid diagnosis of mild to moderate COPD; Significant smoking history (≥10 pack-years of smoking).
|
Baseline period up to study Week 52
|
Rate of asthma exacerbations associated with hospitalizations (subgroups of participants)
Time Frame: Baseline period up to study Week 52
|
The rate of asthma exacerbations associated with hospitalization over 52 weeks before (baseline period) and after initiation of tezepelumab (study period) will be assessed in the following subgroups of participants: BEC ≥300 cells/microliter; BEC <300 cells/microliter; With a clinically-relevant allergy to a perennial aeroallergen; Without a clinically-relevant allergy to a perennial aeroallergen; Participants who identify as Black/African American; Adolescents (12-17 years); Comorbid diagnosis of mild to moderate COPD; Significant smoking history (≥10 pack-years of smoking).
|
Baseline period up to study Week 52
|
Rate of asthma exacerbations associated with emergency department urgent care (ED/UC) visits (subgroups of participants)
Time Frame: Baseline period up to study Week 52
|
The rate of asthma exacerbations associated with ED/UC visits over 52 weeks before (baseline period) and after initiation of tezepelumab (study period) will be assessed in the following subgroups of participants: BEC ≥300 cells/microliter; BEC <300 cells/microliter; With a clinically-relevant allergy to a perennial aeroallergen; Without a clinically-relevant allergy to a perennial aeroallergen; Participants who identify as Black/African American; Adolescents (12-17 years); Comorbid diagnosis of mild to moderate COPD; Significant smoking history (≥10 pack-years of smoking).
|
Baseline period up to study Week 52
|
Rate of asthma exacerbations associated with hospitalizations or ED/UC visits over (subgroups of participants)
Time Frame: Baseline period up to study Week 52
|
The rate of asthma exacerbations associated with hospitalizations or ED/UC visits over 52 weeks before (baseline period) and after initiation of tezepelumab (study period) will be assessed in the following subgroups of participants: BEC ≥300 cells/microliter; BEC <300 cells/microliter; With a clinically-relevant allergy to a perennial aeroallergen; Without a clinically-relevant allergy to a perennial aeroallergen; Participants who identify as Black/African American; Adolescents (12-17 years); Comorbid diagnosis of mild to moderate COPD; Significant smoking history (≥10 pack-years of smoking).
|
Baseline period up to study Week 52
|
Number and type of asthma-related HRU (subgroups of participants)
Time Frame: Baseline period up to study Week 52
|
Number and type of asthma related HRU in the 12-month period before (baseline period) and after initiation of tezepelumab (up to study Week 52- study period) will be assessed in the following subgroups of participants: BEC ≥300 cells/microliter; BEC <300 cells/microliter; With a clinically-relevant allergy to a perennial aeroallergen; Without a clinically-relevant allergy to a perennial aeroallergen; Participants who identify as Black/African American; Adolescents (12-17 years); Comorbid diagnosis of mild to moderate COPD; Significant smoking history (≥10 pack-years of smoking).
|
Baseline period up to study Week 52
|
Duration of asthma-related hospitalizations (subgroups of participants)
Time Frame: Baseline period up to study Week 52
|
Duration of asthma-related hospitalization in the 12- month period before (baseline period) and after initiation of tezepelumab (up to study Week 52- study period) will be assessed in the following subgroups of participants: BEC ≥300 cells/microliter; BEC <300 cells/microliter; With a clinically-relevant allergy to a perennial aeroallergen; Without a clinically-relevant allergy to a perennial aeroallergen; Participants who identify as Black/African American; Adolescents (12-17 years); Comorbid diagnosis of mild to moderate COPD; Significant smoking history (≥10 pack-years of smoking).
|
Baseline period up to study Week 52
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of participants with serious adverse events, adverse events that lead to tezepelumab treatment discontinuation, and adverse events of special interest
Time Frame: Week 0 to Week 52
|
The safety and tolerability of tezepelumab will be assessed.
|
Week 0 to Week 52
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Njira Lugogo., MD., University of Michigan Health. Michigan, USA
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- D5180C00032
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All requests will be evaluated as per the AZ disclosure commitment:
https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure. Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.
IPD Sharing Time Frame
IPD Sharing Access Criteria
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
- SAP
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Asthma
-
Vanderbilt University Medical CenterNot yet recruitingAsthma in Children | Asthma Attack | Asthma Acute | Acute Asthma Exacerbation | Asthma; StatusUnited States
-
University of California, San FranciscoCompletedAsthma in Children | Asthma Attack | Asthma Acute | Asthma ChronicUnited States
-
SingHealth PolyclinicsNot yet recruitingAsthma | Asthma in Children | Asthma Attack | Asthma Acute | Asthma Chronic
-
Johann Wolfgang Goethe University HospitalCompleted
-
Universita di VeronaCompleted
-
Parc de Salut MarActive, not recruitingAsthma in Children | Persistent Asthma | Asthma ExacerbationSpain
-
Forest LaboratoriesCompleted
-
Brunel UniversityKarolinska InstitutetUnknown
-
Johann Wolfgang Goethe University HospitalCompletedExercise-induced AsthmaGermany
Clinical Trials on Tezepelumab
-
AstraZenecaAmgenCompletedAsthmaUnited States, Austria, Canada, France, Germany, Taiwan, Vietnam, Korea, Republic of, Brazil, Turkey, Argentina, Australia, Israel, Poland, Russian Federation, Saudi Arabia, South Africa, Ukraine
-
Asger SverrildAstraZeneca; University Hospitals, Leicester; University Hospital, AntwerpRecruitingCOPD | COPD Exacerbation | Immune System Disorder | Airway Disease | COPD BronchitisUnited Kingdom, Belgium, Denmark
-
AstraZenecaAmgenRecruitingAsthmaUnited States, Canada, Czechia, Korea, Republic of, India, Mexico, Turkey, Chile, Brazil, Thailand, Colombia, Poland, Peru, Malaysia, Philippines
-
AstraZenecaAmgenCompletedRespiratory Tract Diseases | Immune System Diseases | Lung Diseases | Hypersensitivity | Hypersensitivity, Immediate | Bronchial Diseases | Lung Diseases, Obstructive | Asthma | Respiratory HypersensitivityUnited States, Canada, Denmark, United Kingdom, Germany
-
AstraZenecaActive, not recruitingAsthmaUnited States, Belgium, Spain, United Kingdom, France, Argentina, Bulgaria, Germany, Poland, Mexico, Latvia
-
AstraZenecaAmgenCompletedAsthmaUnited Kingdom, South Africa, Hungary
-
University Hospital, MontpellierRecruiting
-
Imperial College LondonAstraZenecaEnrolling by invitationEGPA - Eosinophilic Granulomatosis With PolyangiitisUnited Kingdom
-
AstraZenecaAmgenCompletedChronic Obstructive Pulmonary Disease (COPD)United States, Canada, Denmark, France, United Kingdom, Korea, Republic of, Germany, Israel, Spain, Netherlands
-
AstraZenecaAmgenCompletedAsthmaUnited States, Korea, Republic of, Turkey, Germany, Argentina, Poland, Ukraine